Turn Therapeutics Publishes Peer-Reviewed Data for Lead Atopic Dermatitis Candidate GX-03
TTRX has more than doubled off its 52-week low of $2.57 on elevated volume (2.0× avg).
Summary
Turn Therapeutics announced the peer-reviewed publication of preclinical data for its lead atopic dermatitis candidate, GX-03, showing significant reduction in disease severity in an inflammatory model.
Key Events · Product Development and Regulatory · TTRX
-
Peer-Reviewed Publication
Turn Therapeutics announced the publication of preclinical data for GX-03 in the Journal of Dermatological Treatment.
-
Positive Preclinical Results
The study showed GX-03 significantly reduced disease severity in a murine dermatitis model, achieving a mean investigator global assessment score of 1.44 versus 3.00 in untreated controls (p = 0.0003).
-
Scientific Validation
This is the first in a planned series of publications, providing scientific rationale for GX-03, which is currently in Phase 2 evaluation for moderate-to-severe atopic dermatitis.
-
Upcoming Milestones
Topline results for the Phase 2 trial of GX-03 are expected in mid-2026.
Analysis · TTRX · Life Sciences
This publication provides scientific validation for Turn Therapeutics' lead candidate, GX-03, demonstrating its activity in an inflammatory skin disease model. For a clinical-stage biotechnology company, peer-reviewed data strengthens the scientific rationale behind their drug development, which is crucial for investor confidence and future financing, especially given the company's prior 'going concern' disclosure. This is the first in a planned series of publications, building anticipation for the upcoming Phase 2 topline results in mid-2026.
At the time of this filing, TTRX was trading at $5.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.7M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.